• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

AVEO Oncology names new chief commercial officer

March 11, 2021 By Sean Whooley

AVEO OncologyAVEO Oncology (NSDQ:AVEO) announced that it appointed Mike Ferraresso as its new chief commercial officer.

Boston-based AVEO Oncology said in a news release that Feraresso will manage the company’s commercial strategy and operations, including the commercialization of Fotivda (tivozanib), a differentiated, oral, once-daily, vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI).

Fotivda is approved in the U.S. for treating adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.

“Directly on the heels of Fotivda’s approval, it is a pleasure to announce Mike’s appointment to chief commercial officer,” AVEO president & CEO Michael Bailey said in the release. “Mike’s hard work and dedication has played a crucial role in preparing for our evolution to a commercial organization. I look forward to working with Mike in his new role as we continue to execute on our mission of improving the lives of patients with cancer.”

Ferraresso most recently served as AVEO’s SVP of business analytics & commercial operations, having joined the company in December 2017. He is a veteran of more than 20 years in the commercial pharmaceutical and biotechnology space, having also held roles at Verastem, Infinity Pharmaceuticals, AMAG Pharmaceuticals, Critical Therapeutics, Praecis Pharmaceuticals, Ascent Pediatrics and Muro Pharmaceuticals.

“It is an honor to be taking on this new role at such an exciting time for the company,” Ferraresso said.. “I look forward to continuing to contribute to our evolution into a commercial organization.”

Filed Under: Business/Financial News, Featured, Oncology, Pharmaceuticals Tagged With: AVEO Oncology, Personnel, Personnel Moves

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS